Association of early dexamethasone therapy with mortality in critically Ill COVID-19 patients: a French multicenter study.

ABSTRACT:

Background

Dexamethasone is recommended for COVID-19 patients who require oxygen therapy. However, its effectiveness in reducing mortality and intubation, and its safety, remain debated. We aimed to investigate whether dexamethasone reduces day-28 mortality in unselected patients with critical COVID-19.

Methods

We performed an observational cohort study in consecutive COVID-19 patients admitted to any of 13 French intensive care units (ICUs) in 2020. The primary objective was to determine whether early dexamethasone therapy was associated with day-28 mortality and the secondary objectives were to assess whether early dexamethasone decreased intubation requirements and to collect adverse events.

Results

Of 1058 included patients, 611 (57.75%) received early dexamethaso

SUBMITTER: Raymond M 

PROVIDER: S-EPMC9617242 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature